J. Bachiller-Corral, MD, Assistant Head, A. Boteanu, MD, Assistant Head, M. Vazquez-Diaz, MD, Department Head, Department of Rheumatology, Hospital Universitario Ramón y Cajal, and Irycis (Instituto Ramón y Cajal de investigación sanitaria), Madrid;
J. Bachiller-Corral, MD, Assistant Head, A. Boteanu, MD, Assistant Head, M. Vazquez-Diaz, MD, Department Head, Department of Rheumatology, Hospital Universitario Ramón y Cajal, and Irycis (Instituto Ramón y Cajal de investigación sanitaria), Madrid.
J Rheumatol. 2021 Jul;48(7):1098-1102. doi: 10.3899/jrheum.200755. Epub 2021 Mar 15.
To describe the cohort of patients with inflammatory rheumatic diseases (IRD) hospitalized due to SARS-CoV-2 infection in the Ramón y Cajal Hospital, and to determine the increased risk of severe coronavirus disease 2019 (COVID-19) in patients with no IRD.
This is a retrospective single-center observational study of patients with IRD actively monitored in the Department of Rheumatology who were hospitalized due to COVID-19.
Forty-one (1.8%) out of 2315 patients admitted due to severe SARS-CoV-2 pneumonia suffered from an IRD. The admission OR for patients with IRD was 1.91 against the general population, and it was considerably higher in patients with Sjögren syndrome, vasculitis, and systemic lupus erythematosus. Twenty-seven patients were receiving treatment for IRD with corticosteroids, 23 with conventional DMARDs, 12 with biologics (7 rituximab [RTX], 4 anti-tumor necrosis factor [anti-TNF], and 1 abatacept), and 1 with Janus kinase inhibitors. Ten deaths were registered among patients with IRD. A higher hospitalization rate and a higher number of deaths were observed in patients treated with RTX (OR 12.9) but not in patients treated with anti-TNF (OR 0.9).
Patients with IRD, especially autoimmune diseases and patients treated with RTX, may be at higher risk of severe pneumonia due to SARS-CoV-2 compared to the general population. More studies are needed to analyze this association further in order to help manage these patients during the pandemic.
描述因 SARS-CoV-2 感染而住院的炎症性风湿病 (IRD) 患者队列，并确定无 IRD 的患者患严重 2019 年冠状病毒病 (COVID-19) 的风险增加。
这是一项回顾性单中心观察性研究，涉及在风湿病科接受主动监测的 IRD 患者，这些患者因 COVID-19 住院。
在因严重 SARS-CoV-2 肺炎住院的 2315 名患者中，有 41 名（1.8%）患有 IRD。IRD 患者的入院优势比 (OR) 为 1.91，与普通人群相比，患有干燥综合征、血管炎和系统性红斑狼疮的患者的 OR 明显更高。27 名患者正在接受 IRD 治疗，包括皮质类固醇、23 名接受传统 DMARD 治疗、12 名接受生物制剂（7 名利妥昔单抗 [RTX]、4 名抗肿瘤坏死因子 [抗 TNF] 和 1 名阿巴西普）治疗和 1 名接受 Janus 激酶抑制剂治疗。在 IRD 患者中，有 10 人死亡。与接受 RTX 治疗的患者相比，接受 RTX 治疗的患者的住院率和死亡人数更高（OR 12.9），但接受抗 TNF 治疗的患者（OR 0.9）并非如此。
与普通人群相比，IRD 患者，尤其是自身免疫性疾病患者和接受 RTX 治疗的患者，因 SARS-CoV-2 引起的严重肺炎的风险可能更高。需要进一步研究以进一步分析这种关联，以便在大流行期间帮助管理这些患者。
